140405-36-3
140405-36-3
Chemical Structure
RSVA405
- CAS No.: 140405-36-3
- Formula:C17H20N4O2
- Molecular Weight:312.37
IUPAC Name: (E)-N'-(4-(diethylamino)-2-hydroxybenzylidene)isonicotinohydrazide
InChIKey: GWQPCBPAOAFXSJ-XDHOZWIPSA-N
SMILES: O=C(C1=CC=NC=C1)N/N=C/C2=CC=C(N(CC)CC)C=C2O
Biological Activity: RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RSVA405 | 99.72% | RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RSVA405 (Standard) | ≥98% | RSVA405 (Standard) is the analytical standard of RSVA405 (HY-103238). This product is intended for research and analytical applications. RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AS8351 (Standard) | ≥98% | AS8351 (Standard) is the analytical standard of AS8351 (HY-100744). This product is intended for research and analytical applications. AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aconiazide | Aconiazide (Isonicophen) is a orally active hydrazone derivative of isoniazid, and can be used for study of tuberculosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KM91104 | 98.06% | KM91104 is a cell-permeable V-ATPase a3-b2 inhibitor (IC50 = 2.3 µM). KM91104 reduces the metabolic activity, cell proliferation capacity and V-ATPase subunit protein expression levels of primary human hepatic stellate cells, increases intracellular ATP levels and decreases cytoplasmic pH. KM91104 reduces TLR4 expression on the surface of oligodendrocyte precursor cells, blocks the ENV-TLR4 interaction, and reverses oligodendrocyte myelination defects induced by ENV protein. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ERRγ agonist-1 | 98.02% | ERRγ agonist-1 is a potent ERRγ agonist. ERRγ agonist-1 increases transcriptional activities of ERRγ. ERRγ agonist-1 has the potential for the research of neuropsychological disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SCFSkp2-IN-2 | 99.01% | SCFSkp2-IN-2 (Compound AAA-237) is a Skp2 inhibitor with a KD of 28.77 μM. AAA-237 induces apoptosis of NSCLC cells and shows antitumor activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DY131 | 99.22% | DY131 (GSK 9089) is a potent and selective ERRγ and ERRβ agonist. DY131displays inactive against ERRα, ERα and ERβ. DY131 also inhibits Smo signaling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDZI 2,4OH | HDZI 2,4OH exerts significant anti anxiety activity through GABA receptors. HDZI 2,4OH can penetrate the blood-brain barrier. HDZI 2,4OH exhibits low toxicity in zebrafish. HDZI 2,4OH can be used for research on neurological disorders such as anxiety disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N'-(Pyridin-4-ylmethylene)isonicotinohydrazide | ||||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salinazid | 99.62% | Salinazid is an antituberculous compound. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ftivazide (Standard) | ≥98% | Ftivazide (Standard) is the analytical standard of Ftivazide. This product is intended for research and analytical applications. Ftivazide has anti-tuberculosis activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Khader A, et, al. Novel resveratrol analogues attenuate renal ischemic injury in rats. J Surg Res. 2015 Feb;193(2):807-15. [Content Brief]
- [2]. Vingtdeux V, et, al. Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med. Sep-Oct 2011;17(9-10):1022-30. [Content Brief]
- [3]. Capiralla H, et, al. Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW 264.7 macrophages. FEBS J. 2012 Oct;279(20):3791-9. [Content Brief]
- [4]. Vingtdeux V, et, al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J. 2011 Jan;25(1):219-31. [Content Brief]
